Q1 Earnings Estimate for SYRE Issued By Wedbush

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Stock analysts at Wedbush issued their Q1 2025 EPS estimates for shares of Spyre Therapeutics in a report issued on Friday, November 8th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($0.84) for the quarter. Wedbush currently has a "Outperform" rating and a $45.00 target price on the stock. The consensus estimate for Spyre Therapeutics' current full-year earnings is ($4.18) per share. Wedbush also issued estimates for Spyre Therapeutics' Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.73) EPS and Q4 2025 earnings at ($0.74) EPS.

Several other analysts also recently issued reports on SYRE. Evercore ISI started coverage on Spyre Therapeutics in a research note on Tuesday, July 16th. They issued an "outperform" rating for the company. Guggenheim boosted their target price on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company a "buy" rating in a research report on Friday, October 25th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $46.43.

Spyre Therapeutics Trading Down 0.6 %

SYRE stock traded down $0.23 during mid-day trading on Monday, hitting $39.35. 537,407 shares of the company were exchanged, compared to its average volume of 432,545. Spyre Therapeutics has a 1-year low of $8.75 and a 1-year high of $47.97. The business has a 50 day simple moving average of $30.76 and a 200-day simple moving average of $30.36.

Hedge Funds Weigh In On Spyre Therapeutics

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Spyre Therapeutics during the 2nd quarter worth approximately $130,000. EFG Asset Management North America Corp. acquired a new stake in shares of Spyre Therapeutics in the 2nd quarter valued at $869,000. Bank of New York Mellon Corp bought a new position in shares of Spyre Therapeutics in the 2nd quarter valued at $2,767,000. Rhumbline Advisers acquired a new position in shares of Spyre Therapeutics during the 2nd quarter worth $1,220,000. Finally, TD Asset Management Inc bought a new stake in shares of Spyre Therapeutics during the 2nd quarter worth $827,000. 80.39% of the stock is owned by institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).